{
  "accountCode": "5662516403001",
  "playerCode": "0hVpNUYdY",
  "slidesViewer": true,
  "showSubSlides": false,
  "subSlidesActive": false,
  "chapters": [
    {
      "videoID": "6154971459001",
      "slides": [
        {
          "title": "Fampyra<sup>®</sup> (PR-fampridine) launch Event",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slideP1.JPG",
          "time": 0
        },
        {
          "title": "Treating walking impairment in MS patients",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slideP3.JPG",
          "time": 96
        },
        {
          "title": "Walking impairment in MS",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slideP4.JPG",
          "time": 122
        },
        {
          "title": "Walking difficulties in MS",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slideP5.JPG",
          "time": 160
        },
        {
          "title": "Symptomatic treatments: Motor function and coordination, e.g spasticity, paresis, ataxia, and tremor",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slideP6.JPG",
          "time": 217
        },
        {
          "title": "Prolonged release-fampridine = PR-fampridine",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slideP9.JPG",
          "time": 294
        },
        {
          "title": "Fampridine’s mechanism of action<sup>1,2</sup>",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slideP10.JPG",
          "time": 409
        },
        {
          "title": "PR-fampridine: pharmacokinetic profile",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slideP11.JPG",
          "time": 439
        },
        {
          "title": "Pharmacokinetics and metabolism in healthy volunteers",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slideP12.JPG",
          "time": 567
        },
        {
          "title": "Efficacy data of FAMPYRA",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slideP17.JPG",
          "time": 825
        },
        {
          "title": "Phase III studies MS-F203 and MS-F204",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slideP18.JPG",
          "time": 845
        },
        {
          "title": "MS-F203<sup>1</sup> and MS-F204<sup>2</sup>: study schedule and design",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slideP19.JPG",
          "time": 939
        },
        {
          "title": "MS-F203/4: baseline characteristics",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slideP20.JPG",
          "time": 1052
        },
        {
          "title": "MS-F203/4: primary efficacy endpoint",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slideP21.JPG",
          "time": 1124
        },
        {
          "title": "MS-F203/4: primary efficacy outcome",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slideP22.JPG",
          "time": 1274
        },
        {
          "title": "MS-F203/4 open-label extension: long term efficacy",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slideP23.JPG",
          "time": 1300
        },
        {
          "title": "Treatment with fampridine has demonstrated sustained, clinically meaningful improvements in walking ability, as assessed using the T25-FW in clinical trials and real-world settings (1/2)",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slideP24.JPG",
          "time": 1425
        },
        {
          "title": "Treatment with fampridine has demonstrated sustained, clinically meaningful improvements in walking ability, as assessed using the T25-FW in clinical trials and real-world settings (2/2)",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slideP25.JPG",
          "time": 1526
        },
        {
          "title": "Phase III Pivotal Study: ENHANCE",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slideP26.JPG",
          "time": 1574
        },
        {
          "title": "ENHANCE: objective and study design",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slideP27.JPG",
          "time": 1638
        },
        {
          "title": "ENHANCE: study design",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slideP28.JPG",
          "time": 1721
        },
        {
          "title": "ENHANCE: endpoints",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slideP29.JPG",
          "time": 1755
        },
        {
          "title": "Sustained clinically meaningful improvements in patients perception of walking ability, as measured by the MSWS‑12, have also been observed in both clinical trials and observational studies (1/2)",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slideP30.JPG",
          "time": 1772
        },
        {
          "title": "Fampridine has a favourable long-term safety and tolerability profile with the majority of AEs observed in the clinical trial programme being mild to moderate in severity",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slideP31.JPG",
          "time": 1800
        },
        {
          "title": "The positive benefit-risk profile of fampridine established through clinical trials is supported by extensive post-marketing surveillance and real-world studies, with no new safety signals identified",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slideP32.JPG",
          "time": 1925
        },
        {
          "title": "Warning and precautions<sup>1</sup>",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slideP33.JPG",
          "time": 1979
        },
        {
          "title": "FAMPYRA<sup>®</sup>",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slideP7.JPG",
          "time": 2081
        },
        {
          "title": "3 Easy Steps Until FAMPYRA<sup>®</sup>",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slideP14.JPG",
          "time": 2157
        },
        {
          "title": "Interactions<sup>1</sup>",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slideP15.JPG",
          "time": 2203
        },
        {
          "title": "Pregnancy / Lactation",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slideP16.JPG",
          "time": 2215
        },
        {
          "title": "Rolle von Frampyra..",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slidePD1.jpg",
          "time": 2240
        },
        {
          "title": "Welche patienten sollten zur reha gehen?",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slidePD2.jpg",
          "time": 2269
        },
        {
          "title": "Verschiedene Patientengruppen mit verschiedenen..",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slidePD3.jpg",
          "time": 2285
        },
        {
          "title": "Langjährige MS, ggfs. Fortgeschrittene..",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slidePD4.jpg",
          "time": 2313
        },
        {
          "title": "Möglichkeiten der Reha in Montana:",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slidePD5.jpg",
          "time": 2330
        },
        {
          "title": "Thema Geräte für die motorische..",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slidePD6.jpg",
          "time": 2360
        },
        {
          "title": "Grundlagen des klassischen..",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slidePD7.jpg",
          "time": 2440
        },
        {
          "title": "Traditionell:",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slidePD8.jpg",
          "time": 2469
        },
        {
          "title": "Geräte-gestütze rehabilitation..",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slidePD9.jpg",
          "time": 2490
        },
        {
          "title": "Gerätegestütztes Gangtraining",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slidePD10.jpg",
          "time": 2535
        },
        {
          "title": "Laufbandtraining, ggfs. mit partieller..",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slidePD11.jpg",
          "time": 2555
        },
        {
          "title": "Vereinfachter EDSS",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slidePD13.jpg",
          "time": 2576
        },
        {
          "title": "Product information for professionals",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slidePD12.jpg",
          "time": 2620
        },
        {
          "title": "3 easy steps until FAMPYRA",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slidePD16.jpg",
          "time": 2673
        },
        {
          "title": "How to measure walking in MS",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slidePD20.jpg",
          "time": 2710
        },
        {
          "title": "Treatment with PR-Fampridine: EDSS 4.0",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slidePD20.jpg",
          "time": 2777
        },
        {
          "title": "6‐Minuten‐Gehtest",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slidePD21.jpg",
          "time": 2851
        },
        {
          "title": "Timed up and go test",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slidePD22.jpg",
          "time": 2882
        },
        {
          "title": "Wichtig sind aber auch",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slidePD23.jpg",
          "time": 2956
        },
        {
          "title": "Fallvignette: Frau S..",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slidePD24.jpg",
          "time": 3101
        },
        {
          "title": "Relevante Eintrittsbefunde",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slidePD25.jpg",
          "time": 3219
        },
        {
          "title": "Cave",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slidePD26.jpg",
          "time": 3301
        },
        {
          "title": "Assessment / Reassessment",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slidePD27.jpg",
          "time": 3427
        },
        {
          "title": "Assessment of MS2S-12",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slidePD29.jpg",
          "time": 3496
        },
        {
          "title": "MSWS-12",
          "imageUrl": "https://cp-author.biogen-support.com/content/dam/commercial-eu/neurology/microsites/landingpages/en/on-demand/bern/slides/slidePD30.jpg",
          "time": 3623
        }
      ]
    }
  ]
}
